U.S. markets open in 1 hour 57 minutes
  • S&P Futures

    4,419.50
    -18.50 (-0.42%)
     
  • Dow Futures

    34,539.00
    -105.00 (-0.30%)
     
  • Nasdaq Futures

    15,213.50
    -90.00 (-0.59%)
     
  • Russell 2000 Futures

    2,243.70
    -11.50 (-0.51%)
     
  • Crude Oil

    73.09
    -0.21 (-0.29%)
     
  • Gold

    1,752.90
    +3.10 (+0.18%)
     
  • Silver

    22.58
    -0.10 (-0.46%)
     
  • EUR/USD

    1.1725
    -0.0022 (-0.19%)
     
  • 10-Yr Bond

    1.4100
    0.0000 (0.00%)
     
  • Vix

    20.13
    -0.74 (-3.55%)
     
  • GBP/USD

    1.3679
    -0.0041 (-0.30%)
     
  • USD/JPY

    110.5050
    +0.2040 (+0.18%)
     
  • BTC-USD

    41,421.52
    -2,351.45 (-5.37%)
     
  • CMC Crypto 200

    1,024.64
    -84.28 (-7.60%)
     
  • FTSE 100

    7,061.35
    -17.00 (-0.24%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Biogen BIIB and its partner Eisai announced that the FDA has approved an update to the label of its newly approved drug for Alzheimer’s disease, Aduhelm (aducanumab) that clarifies the patient population in which the controversial drug was tested.

The updated label will mention that Aduhelm treatment should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. For earlier or later stages of the disease, there is no safety or effectiveness data available to support initiating treatment with Aduhelm.

The FDA approved Aduhelm, on an accelerated basis, in June to reduce the accumulation of amyloid beta plaques, a sticky protein, in the brain, which is believed to lead to progression of Alzheimer’s disease.

Aduhelm has become the first medicine to be approved to reduce the clinical decline associated with this devastating disease and targeting the underlying cause of the disease. It should bring in huge revenues for Biogen by meaningfully changing the course of Alzheimer’s treatment.

However, the controversial FDA decision generated several headlines. The FDA approved Aduhelm despite an FDA advisory committee voting against its approval in November last year due to mixed outcomes data from ENGAGE and EMERGE phase III studies.

The FDA approval faced a lot of criticism as some analysts believed the drug was not backed by strong evidence of efficacy. Aduhelm also comes with a hefty price tag of $56,000 a year, which was widely condemned.

However, another group of analysts cheered the drug’s approval despite questionable study results because of the drug’s ability to remove amyloid from the brain and its potential to provide meaningful benefit in preventing progression of this disease.

The purpose of the latest label update is to clarify the patient population that was studied across the ENGAGE and EMERGE phase III studies and the phase Ib PRIME study, based on which Aduhelm was approved.

The new label will narrow the patient population for whom Aduhelm can now be prescribed. However, it accurately reflects the right patients who should be prescribed the drug, which should help doctors and payers clearly decide who is eligible for Aduhelm. Though Aduhelm is reportedly now just eligible for 1 million-2 million patients out of 6 million Alzheimer’s patients in the United States, it should still bring in significant sales for Biogen. This clearly explains why shares shot up around 4% on Thursday despite its eligible patient population being narrowed.

Biogen’s shares have risen 50.8% this year so far against the industry’s decrease of 2.2% in the same time frame.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Alzheimer’s, a fatal condition that causes progressive decline in memory, has always been a highly challenging area, and not much progress has been made despite significant investments (both funds and resources). Several companies have failed to develop safe and effective treatment options to treat this deadly brain disease. Several large pharma companies, including Roche RHHBY, Amgen AMGN, Novartis NVS, Merck, Pfizer, Lilly and AstraZeneca stopped development of their AD candidates in the last few years either due to low possibility of success or safety concerns.

Despite the setbacks, the companies continue to invest heavily in developing AD treatments, given the high commercial potential in this market.

Biogen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novartis AG (NVS) : Free Stock Analysis Report

Biogen Inc. (BIIB) : Free Stock Analysis Report

Roche Holding AG (RHHBY) : Free Stock Analysis Report

Amgen Inc. (AMGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research